Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
Quoin Pharmaceuticals Ltd., a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, reported significant progress in Q2 2026 including FDA conditional approval of QYLEKI™ (QRX003) brand name, positive clinical updates from pediatric compassionate use program in Netherton Syndrome, receipt of a U.S. patent allowan…
Our Bond, Inc. (NASDAQ: OBAI), an AI-powered preventative personal security platform provider, reported Q2 2026 results showing a 28% reduction in net loss, 41% decline in operating expenses, and a 37% increase in cash to $5.2 million. The company is gaining significant traction with cities internationally purchasing licenses for residents and city…
Sky Harbour builds and leases private aviation hangars. With a market cap near $883M, improving momentum, and high short interest, the stock offers a speculative long opportunity for patient traders willing to accept elevated operational and leverage risk. Entry $10.98, stop $9.00, target $15.00. Long-term (180 trading days) plan.
Sandisk's sharp sell-off in July created an actionable entry for traders. The company still sits on massive AI-driven demand visibility, attractive cash flows and a heavy buyback; this trade targets a recovery toward prior highs while using a tight stop to protect from cyclical downside.
Maris-Tech Ltd., a Nasdaq-listed provider of advanced defense technology, has achieved the AS9100D quality management certification, qualifying the company to act as a prime contractor in defense and aerospace programs both in Israel and internationally. This certification, mandatory for many government tenders, supports Maris-Tech’s strategic shif…
Nexera Technologies Ltd's majority-owned subsidiary Fort Technology reported record first-half 2026 results with revenue growth of 49% to $7.36 million and a 145% increase in gross profit. This growth was driven by higher sales volume on Amazon Marketplace, especially in the UK and Europe. Fort commenced trading on Nasdaq in June 2026 and is expand…
Scienture Holdings, Inc. (NASDAQ: SCNX) reported a remarkable revenue increase of approximately 510% sequentially in Q2 2026 compared to Q1 2026, reaching $343,639 with gross margins near 98%. The company achieved a 48% year-over-year improvement in operating loss and narrowed net loss by 58%. Key commercial milestones include the launch of their s…
Applied Materials pulled back sharply from its highs, presenting a tradeable entry for disciplined longs. The business sits squarely in the AI-driven semiconductor capex cycle, posts healthy free cash flow, and carries modest leverage. Valuation is premium, so risk control and staged targets are essential.
Duolingo is intentionally sacrificing short-term revenue growth to chase 100 million daily active users (DAU) by 2028. With 56.5M DAU today, 27% revenue growth, $407.9M free cash flow and a $6.74B market cap, the risk/reward looks asymmetric for a mid-term long swing if DAU acceleration resumes. This trade lays out a clear entry at $144.0547, a $22…
Trident Digital Tech Holdings Ltd., listed on Nasdaq (TDTH), announced that its 50/50 joint venture, Trident Aliska Digital Tech Ghana Ltd., projects a Sikaflow platform revenue run-rate of approximately US$65.5 million annualized by December 2026. The platform, launched in June 2026, is designed to digitize and formalize transactions for micro, sm…
Palantir's latest quarter made skeptics uncomfortable: 93% revenue growth, a pronounced commercial acceleration and a sharp margin expansion. Technical momentum, declining short interest and ample free cash flow create a favorable set-up for a mid-term long. This trade plan outlines an entry at $175.00, a stop at $160.00 and a target of $220.00 ove…
Safe Pro Group Inc. announced record second quarter 2026 financial results with revenues surging 1,336% year-over-year to $1.33 million driven by multiple U.S. government contracts for their AI-powered NODE and SPOTD threat detection and mapping solutions. The company's AI gross margin reached 75%, highlighting high scalability and profitability. K…
Quince Therapeutics completed its acquisition of Orphai Therapeutics, adding the inhaled rapamycin formulation LAM-001 to its pipeline targeting serious pulmonary diseases. The company initiated a Phase 2b trial in pulmonary hypertension associated with interstitial lung disease (PH-ILD) and expects key data from ongoing trials in bronchiolitis obl…
Lantheus Holdings announced FDA approval of TAUKLARIFY™ (florquinitau F 18 injection), a radiodiagnostic PET imaging agent that identifies tau neurofibrillary tangle pathology in adults with cognitive impairment being evaluated for Alzheimer's disease. Supported by clinical trials demonstrating high accuracy and safety, TAUKLARIFY complements exist…
CSP Inc., a US-based security and technology solutions company, announced its third quarter fiscal 2026 financial results, showing stable sales with a slight decline due to hardware supply delays but improved gross margins and a 100% customer renewal rate for its AZT PROTECT product. The company secured significant new contracts including a large m…
Replimune Group, Inc. announced FDA accelerated approval of TUDRIQEV (vusolimogene oderparepvec-wtpg) in combination with nivolumab for treating unresectable advanced cutaneous melanoma patients who progressed after PD-1 antibody treatment. The company is preparing to launch the product in the U.S. within 60 days. They strengthened their commercial…
Annovis Bio reports successful full enrollment of its pivotal Phase 3 clinical trial for buntanetap in early Alzheimer's disease, surpassing target patient numbers. The company also progresses its Parkinson's disease open-label extension study and prepares for initial data readout in early 2027, supporting upcoming regulatory steps. Financially, An…
Foremost Clean Energy Ltd. announced the grant of 68,000 stock options to certain officers, employees, and consultants under its Long-Term Incentive Plan. The options have an exercise price of $1.87, vest over three years, and have a five-year term. The company focuses on uranium, lithium, and gold exploration in North America, supporting carbon-fr…
Galectin Therapeutics reported Q2 2026 financial results and provided updates on its lead drug belapectin targeting MASH cirrhosis and portal hypertension. The company reached agreement with the FDA on key design elements of the planned registrational Phase 3 trial, validating its regulatory pathway. New clinical data reinforcing belapectin's poten…
IES Holdings, Inc. announced that its President & CEO and CFO will present at the Midwest IDEAS Investor Conference on August 27, 2026, in Chicago. The presentation will be webcast and materials will be available on their investor relations website. IES is a US-based company specializing in electrical and technology systems installation and infrast…
GT Biopharma announced its second quarter 2026 financial results, reporting ongoing Phase 1 clinical trials for two TriKE candidates targeting hematologic malignancies and solid tumors, respectively. The company has $5.1 million in cash expected to fund operations through Q4 2026, with R&D and SG&A expenses rising due to trial activity and marketin…
PMV Pharmaceuticals reported second quarter 2026 financial results highlighting completion of enrollment for the Phase 2 monotherapy portion of the PYNNACLE clinical trial for rezatapopt targeting platinum-resistant/refractory ovarian cancer patients. The company plans to submit a New Drug Application (NDA) in Q1 2027. Cash position stands at $79.4…
Dycom Industries, Inc., a provider of specialty contracting services to telecommunications and utility sectors, will hold its fiscal 2027 second quarter results call on August 26, 2026. The company plans to release its financial results earlier that day, with a conference call and webcast to follow for investors and interested parties.
Allarity Therapeutics reported Q2 2026 financial results showing a solid cash position of $26.9 million and operational progress including a key U.S. patent granting long-term exclusivity for its stenoparib-specific companion diagnostic to 2042. The company completed its Phase 3-ready stenoparib API manufacturing campaign ahead of schedule, obtaine…
Evaxion A/S, a clinical-stage TechBio company utilizing its AI-Immunology platform for vaccine development, announces it will release its second quarter 2026 financial results and provide a business update on August 20, 2026. The company will host a conference call and webcast presenting these details to investors and analysts.
